Form 4: Director Sells AMPH Shares via 10b5-1 Plan

Amphastar Pharmaceuticals Director Floyd F. Petersen sold 500 shares of common stock for $20.8315 per share under a pre-arranged trading plan.

Summary

• Director Floyd F. Petersen sold 500 shares of Amphastar Pharmaceuticals, Inc. common stock.
• The transaction occurred on August 1, 2025.
• The shares were sold at a weighted average price of $20.8315, with individual transaction prices ranging from $20.485 to $21.105.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2024.
• Following the sale, Petersen directly owns 77,031 shares of Amphastar Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sale of shares by a director, while a reduction in insider ownership, was conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a scheduled liquidity event rather than a reaction to new company-specific information. This makes the transaction largely neutral in terms of immediate sentiment.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled transaction for personal financial planning rather than a reaction to new, undisclosed company information.

Negatives

• A director's sale of shares reduces insider ownership, which can sometimes be interpreted negatively by the market, although the pre-planned nature mitigates this concern.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but its pre-planned nature under Rule 10b5-1 typically lessens concerns about its implications for the company's future prospects.

Key Dates

Recommendation

The sale of 500 shares by a director, while a reduction in insider ownership, was executed under a pre-arranged Rule 10b5-1 trading plan. This indicates a scheduled transaction for personal financial planning rather than a reaction to new, undisclosed negative information about the company. The relatively small number of shares sold compared to the director's remaining holdings (77,031 shares) and the company's overall market capitalization suggests this transaction alone is not a strong signal for a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as this specific filing does not provide new information that would fundamentally alter the investment outlook.

Keywords

Amphastar Pharmaceuticals, AMPH, Insider Trading, Form 4, Stock Sale, Director, Floyd F. Petersen, 10b5-1 Plan